SNDX

Syndax Pharmaceuticals Inc

14.29

Nov 03 • 3:59 PM ET +1.19 (9.08%)

14.20

Aftermarket • 5:37 PM ET -0.09 (-0.63%)

Healthcare Biotechnology USA Small NASD

Today, 10:46 AMSyndax posts 82% Q3 revenue growth as Revuforj rebounds and halts axatilimab IPF program after Phase 2 failure

Peers: KURA INCY RIGL AAPG DMRA GERN BMEA TNGX CGON JNJ

| Held by: VTI XBI IWM VXF IWO VTWO IBB SCHA VHT FYC

Scroll to Statements

Index	RUT
Market Cap	1.28B
Enterprise Value	1.44B
Income	-209.48M
Sales	289.68M
Book/sh	-0.19
Cash/sh	4.78
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	298
IPO	Mar 03, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	4.41
P/B	-
P/C	2.99
P/FCF	-
EV/EBITDA	-
EV/Sales	4.97
Quick Ratio	4.37
Current Ratio	4.69
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-2.37
EPS next Y	-0.98
EPS next Q	-0.52
EPS this Y	34.69%
EPS next Y	54.24%
EPS next 5Y	-
EPS past 3/5Y	-10.26% -12.05%
Sales past 3/5Y	- 157.68%
EPS Y/Y TTM	34.52%
Sales Y/Y TTM	159.68%
EPS Q/Q	21.46%
Sales Q/Q	81.59%
Earnings	Nov 02 AMC
EPS/Sales Surpr.	-9.11% 2.36%

Insider Own	9.12%
Insider Trans	-1.38%
Inst Own	115.37%
Inst Trans	10.39%
ROA	-33.67%
ROE	-426.43%
ROIC	-36.64%
Gross Margin	92.21%
Oper. Margin	-61.67%
Profit Margin	-72.32%
SMA20	0.50%
SMA50	-15.67%
SMA200	-29.14%
Trades

Shs Outstand	89.99M
Shs Float	81.16M
Short Float	22.18%
Short Ratio	9.08
Short Interest	18.00M
52W High	25.59 -44.16%
52W Low	12.80 11.68%
Volatility	5.93% 4.99%
ATR (14)	0.82
RSI (14)	44.46
Beta	0.46
Rel Volume	2.51
Avg Volume	1.98M
Volume	4,975,492

Perf Week	4.38%
Perf Month	-19.85%
Perf Quarter	-28.26%
Perf Half Y	-28.91%
Perf YTD	-31.98%
Perf Year	3.85%
Perf 3Y	-3.45%
Perf 5Y	-29.40%
Perf 10Y	37.80%
Recom	1.09
Target Price	35.90
Prev Close	13.10
Price	14.29
Change %	9.08%

Consensus

Strong Buy

Avg. Price Target

$35.90

Implied Upside

+151.2%

Analysts13incl. previous ratings

Rating Distribution12 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 16, 2025	Resumed	HH.C. Wainwright	Buy	$40	+179.9%
Sep 10, 2025	Resumed	SStifel	Buy	$44	+207.9%
Sep 04, 2025	Resumed	GGuggenheim	Buy	$34	+137.9%
Aug 05, 2025	Reiterated	BBTIG Research	Buy	$43 → $56	+291.9%
Jul 10, 2025	Initiated	GGoldman	Buy	$18	+26.0%
Oct 24, 2024	Initiated	UUBS	Buy	$37	+158.9%
Jun 28, 2024	Initiated	JJefferies	Buy	$37	+158.9%
Jan 31, 2024	Downgrade	BScotiabank	Sector Outperform → Sector Perform	$36 → $23	+61.0%
Dec 22, 2023	Initiated	MMizuho	Buy	$45	+214.9%
Oct 25, 2023	Initiated	BBofA Securities	Buy	$29	+102.9%
Oct 11, 2023	Initiated	GGoldman	Buy	$30	+109.9%
Jul 27, 2023	Initiated	BScotiabank	Sector Outperform
Jul 11, 2023	Initiated	GGuggenheim	Buy	$40	+179.9%
Apr 17, 2023	Resumed	BBTIG Research	Buy	$34	+137.9%
Jan 31, 2023	Initiated	SStifel	Buy	$37	+158.9%
Jan 03, 2023	Initiated	JJP Morgan	Overweight	$41	+186.9%
Jul 28, 2022	Resumed	RB. Riley Securities	Buy	$31	+116.9%
Apr 11, 2022	Initiated	HH.C. Wainwright	Buy	$31	+116.9%
Feb 15, 2022	Initiated	GGoldman	Buy	$37	+158.9%
Jun 04, 2021	Resumed	RRobert W. Baird	Outperform	$30 → $31	+116.9%

Nov-02-26 11:30PM	Syndax: Q3 Earnings Snapshot (Associated Press) +9.08%
07:34PM	Syndax Misses On EPS But Revuforj Rebound And Higher Niktimvo Margin Guide Sharpen The Commercial Story As Pipeline Setbacks Hang Over The Stock (Earnings Whispers)
04:01PM	Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
04:01PM	Syndax Announces CFO Transition - Aaron A. Ondrey Appointed Chief Financial Officer (GlobeNewswire)
Oct-30-26 09:01AM	Syndax's Revuforj (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases (GlobeNewswire)
07:00AM	Loading…
07:00AM	Syndax Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-26-26 01:40PM	Syndax Must Show Revuforge's New-Patient Slump Was A Blip, Not A Trend (Earnings Whispers)
07:00AM	Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 (GlobeNewswire)
Oct-15-26 04:01PM	Syndax's Revuforj (revumenib) Named to TIME's Best Inventions of 2026 List (GlobeNewswire) -5.49%
Oct-14-26 09:31AM	J&J earnings set negative tone; Shkreli vs. the FTC (BioPharma Dive)
Oct-13-26 11:24AM	Syndax Pharmaceuticals Stock Plunges. A Failed Trial Deals Blow to Growth Plans. (Barrons.com) -15.71%
Oct-12-26 06:11PM	SNDX Stock Slumps 16% After-Hours Whats Driving The Selloff? (Stocktwits)
04:36PM	Syndax Pharmaceuticals stock tumbles on failed IPF trial (Investing.com)
04:01PM	Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Oct-02-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
04:01PM	Loading…
Sep-04-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-01-26 07:00AM	Syndax Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-05-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
01:04AM	Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ... (GuruFocus.com)
Aug-04-26 04:08PM	Syndax: Q2 Earnings Snapshot (Associated Press)
04:01PM	Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-26 07:00AM	Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026 (GlobeNewswire)
Jul-14-26 08:00AM	Syndax to Highlight Late-Stage Programs and Unveil New Pipeline Assets at R&D Event (GlobeNewswire) +5.42%
Jul-01-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-11-26 07:03AM	Syndax Showcases Revuforj (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 (GlobeNewswire)
07:00AM	Syndax Announces Publication of SAVE Data on Revuforj (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology (GlobeNewswire)
Jun-04-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes (GlobeNewswire)
Jun-02-26 04:01PM	Syndax Highlights Revuforj (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data (GlobeNewswire)
Jun-01-26 07:00AM	Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 (GlobeNewswire)
05:01PM	Loading…
May-21-26 05:01PM	Syndax Announces Four Revuforj (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data (GlobeNewswire)
May-20-26 07:00AM	Syndax Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-12-26 10:31AM	Syndax Highlights 12 Revuforj (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition (GlobeNewswire)
May-06-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-26 03:18AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -10.83%
Apr-30-26 04:22PM	Syndax: Q1 Earnings Snapshot (Associated Press)
04:01PM	Syndax Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
Apr-24-26 07:00AM	Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026 (GlobeNewswire)
Apr-03-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-09-26 11:17AM	uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts (24/7 Wall St.) +8.20%
Mar-04-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-02-26 02:57AM	Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs (Insider Monkey)
Feb-27-26 06:46AM	Syndax Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) +5.03%
12:06AM	Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
Feb-26-26 06:00PM	Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:47PM	Syndax: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-23-26 07:00AM	Syndax Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-19-26 07:00AM	Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 (GlobeNewswire)
Feb-15-26 08:05AM	Syndax Pharmaceuticals Highlights Revuforj, Niktimvo Sales Surge and 2026 Milestones at Guggenheim Conf (MarketBeat)
Feb-14-26 01:29AM	BofA Raised Syndax (SNDX) PT to $28, Cites Heavy Pre-Announcements Lowering Earnings Impact (Insider Monkey)
Feb-05-26 07:00AM	Syndax Announces Participation at the 2026 Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Feb-04-26 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-19-26 05:17PM	Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory (Insider Monkey)
Jan-12-26 07:00AM	Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:00AM	Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj (revumenib) Outside the U.S. (GlobeNewswire) +8.70%
Jan-05-26 07:00AM	Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.07%
Dec-12-25 07:00AM	Revuforj (revumenib) Named Best New Drug at the Scrip Awards 2025 (GlobeNewswire)
Dec-08-25 06:50AM	Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum (GlobeNewswire)
Dec-03-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-01-25 07:00AM	Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-28-25 11:57AM	Barclays Raises Syndax (SNDX) PT to $35 on Positive Management Update, Model Rerating (Insider Monkey)
Nov-16-25 10:07PM	JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains "Overweight" Rating (Insider Monkey)
Nov-11-25 01:07PM	Syndax Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily) +12.79%
Nov-07-25 10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
Nov-06-25 11:23AM	ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth (Zacks)
11:18AM	TEVA Q3 Earnings & Revenues Beat, Austedo Sales View Raised, Stock Up (Zacks)
Nov-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 06:03PM	Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +11.56%
Nov-03-25 05:35PM	Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:29PM	Syndax: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
09:08AM	Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 (GlobeNewswire)
09:08AM	Syndax Announces Compelling Revuforj (revumenib) and Niktimvo (axatilimab-csfr) Data Accepted for Presentation at ASH 2025 (GlobeNewswire)
Oct-31-25 09:25AM	Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-30-25 07:00AM	Syndax Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-28-25 10:00AM	Analysts Estimate Qiagen (QGEN) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-25 07:00AM	Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025 (GlobeNewswire)
Oct-24-25 01:58PM	Syndax Announces FDA Approval of Revuforj (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia (GlobeNewswire) -7.83%
Oct-04-25 04:54PM	Syndax's Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision (Insider Monkey)
Oct-03-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +5.13%
Sep-19-25 07:00AM	Syndax's Revuforj (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia (GlobeNewswire)
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -5.05%
Sep-10-25 09:51AM	Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls (The Fly)
Sep-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +5.25%
Sep-01-25 09:55AM	Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade (Zacks)
Aug-28-25 01:59PM	Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise (Zacks)
Aug-26-25 07:00AM	Syndax Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-18-25 11:42PM	Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals (Insider Monkey)
Aug-17-25 11:41PM	BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo (Insider Monkey)
Aug-14-25 09:55AM	Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? (Zacks) +9.52%
Aug-13-25 01:15AM	FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals (Insider Monkey)
Aug-06-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
11:05AM	Citi ups Syndax target, opens upside catalyst watch (TipRanks)
Aug-04-25 05:15PM	Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +21.10%
04:11PM	Syndax: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 12:00PM	All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy (Zacks) +8.15%
10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline (Zacks)
09:55AM	Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Podlesak Dennis	Director	Oct 29 '26	Option Exercise	11.81	8,000	94,480	247,763	Oct 30 07:09 PM
Podlesak Dennis	Director	Oct 29 '26	Sale	14.21	8,000	113,716	239,763	Oct 30 07:09 PM
DENNIS G PODLESAK	Director	Oct 29 '26	Proposed Sale	14.32	8,000	114,560		Oct 29 04:20 PM
Metzger Michael A	Chief Executive Officer	Jul 08 '26	Option Exercise	6.38	32,375	206,552	517,218	Jul 09 04:54 PM
Metzger Michael A	Chief Executive Officer	Jul 08 '26	Sale	24.24	32,375	784,776	484,843	Jul 09 04:54 PM
MICHAEL METZGER	Director	Jul 08 '26	Proposed Sale	23.24	32,375	752,395		Jul 08 04:39 PM
Botwood Nicholas A.J.	Head of R&D, CMO	Jun 12 '26	Option Exercise	13.82	31,235	431,668	92,120	Jun 12 05:09 PM
Botwood Nicholas A.J.	Head of R&D, CMO	Jun 11 '26	Option Exercise	13.82	22,515	311,157	95,165	Jun 12 05:09 PM
Botwood Nicholas A.J.	Head of R&D, CMO	Jun 11 '26	Sale	18.00	34,280	617,040	60,885	Jun 12 05:09 PM
Botwood Nicholas A.J.	Head of R&D, CMO	Jun 12 '26	Sale	18.14	31,235	566,603	60,885	Jun 12 05:09 PM
Botwood Nicholas A.J.	Officer	Jun 12 '26	Proposed Sale	18.14	31,235	566,693		Jun 12 04:10 PM
Botwood Nicholas A.J.	Officer	Jun 11 '26	Proposed Sale	17.78	34,280	609,435		Jun 11 04:12 PM
Goldan Keith A.	Chief Financial Officer	Jun 01 '26	Sale	18.99	1,177	22,351	139,252	Jun 02 04:30 PM
Metzger Michael A	Chief Executive Officer	Jun 01 '26	Sale	18.99	6,847	130,025	484,843	Jun 02 04:30 PM
Goldan Keith A.	Officer	Jun 01 '26	Proposed Sale	18.99	1,177	22,352		Jun 01 03:59 PM
Metzger Michael A	Officer	Jun 01 '26	Proposed Sale	18.99	6,847	130,028		Jun 01 03:54 PM
Metzger Michael A	Chief Executive Officer	Feb 09 '26	Sale	21.03	17,159	360,819	491,690	Feb 10 09:00 AM
Goldan Keith A.	Chief Financial Officer	Feb 09 '26	Sale	21.03	3,410	71,705	140,429	Feb 10 08:59 AM
Metzger Michael A	Officer	Feb 09 '26	Proposed Sale	21.03	17,159	360,826		Feb 09 03:57 PM
Goldan Keith A.	Officer	Feb 09 '26	Proposed Sale	21.03	3,410	71,707		Feb 09 03:42 PM
Metzger Michael A	Chief Executive Officer	Feb 06 '26	Sale	20.62	7,412	152,835	508,849	Feb 06 05:54 PM
Goldan Keith A.	Chief Financial Officer	Feb 06 '26	Sale	20.62	2,082	42,931	143,839	Feb 06 05:53 PM
Metzger Michael A	Officer	Feb 06 '26	Proposed Sale	20.62	7,412	152,836		Feb 06 03:47 PM
Goldan Keith A.	Officer	Feb 06 '26	Proposed Sale	20.62	2,082	42,931		Feb 06 03:43 PM

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include Revuforj and Niktimvo. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

CEO & DirectorMr. Michael A. Metzger M.B.A.

CFOMr. Keith Alan Goldan CPA

General Counsel & Corporate SecretaryMr. Luke J. Albrecht J.D.

Chief Commercial OfficerMr. Steven Closter

MBBSDr. Nicholas A.J. Botwood B.Sc.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNDX

Syndax Pharmaceuticals Inc

Upgrade your Finviz experience